Thrombotic Thrombocytopenic Purpura

Click “In Their Blood” for a review article about TTP from the University of Kansas (KU) Medical Center’s Pathology Department. The article highlights the early research into ADAMTS13‘s role in VWF metabolism, the early successes of PLEX therapy, and the current availability of the therapeutics caplacizumab and the ADAMTS13 concentrate, Adzynma. Also featured is the […]

Comments (0)

Bleeding Disorders

Jul 29 2025

george

July 2025 QQ: Hemophilia Rebalancing Therapy

Our July 2025 Quick Question asked, “Which is a hemophilia ‘rebalancing’ therapeutic?” The question attracted a modest 22 participants, perhaps an indication that rebalancing therapy was only FDA-approved in 2025 and awaits approval in Canada and Europe. Here are your responses… Valoctocogene roxaparvovec-rvox (ROCTAVIAN) 3 (14%) Efanesoctocog alfa (ALTUVIIIO) 1 (4%) Emicizumab (HemLibra) 7 (32%) […]

Comments (0)

Quick Question Archive

Jul 26 2025

george

Status of Gene-based Hemophilia A and B Therapy

Click here for an open-access, in-depth, illustrated review of the worldwide status of gene-based HA and HB therapy: Glasner MF, Pipe S, Miesbach W. Gene-based therapies for hemophilia. Res Pract Thromb Haemost. 2025;9:102870. doi: 10.1016/j.rpth.2025.102870. PMID: 40488175; PMCID: PMC12143782.

Bleeding Disorders

Autoimmune Acquired Coagulation Factor Deficiencies

Click here for the open-access review of Ichinose A, Osaki T, Souri M. Diagnosis and treatment of autoimmune acquired coagulation factor deficiencies: an evidence-based review of Japanese practice. Semin Thromb Hemost. 2025;51:491-505. doi: 10.1055/s-0044-1787188. Epub 2024 Jun 12. PMID: 38866039. Abstract Among the acquired coagulation factor deficiencies, autoimmune coagulation factor deficiencies (AiCFD) are rare and […]

Bleeding Disorders

Postpartum DIC

Check with your medical library for this review, dated 7-18-25. Wolfovitz A, Brenner B, Solt I. Postpartum disseminated intravascular coagulation: A comprehensive review of pathophysiology, diagnosis, management, and prevention. Semin Thromb Hemost. doi: 10.1055/a-2645-2845. Epub ahead of print. PMID: 40680793. Abstract Disseminated intravascular coagulation (DIC) in the postpartum period is a rare but potentially life-threatening […]

Fibrinolysis

Genetic Study on VWD Variants

Click the JTH May issue abstract link: Friedman RK, Heath AS, Huffman JE, et al; National Heart, Lung and Blood Institute (NHLBI) Trans-Omics for Precision Medicine (TOPMed) Consortium; TOPMed Hematology & Hemostasis Working Group; VA Million Veteran Program; Blangero J, Fornage M, Kooperberg C, et al. Genetic study of von Willebrand factor antigen levels ≤ […]

Bleeding Disorders

July 2025 Quick Question: Hemophilia Therapeutics

At the June 21–25 ISTH meeting in Washington, DC, we heard several quality presentations describing the new hemophilia treatment materials, including updated EHL concentrates plus the bypassing, rebalancing, and gene transfer therapies. In follow-up, our July 2025 Quick Question asks you to select the choice that represents the recently approved rebalancing therapies. Please make your […]

Bleeding Disorders

Differential Discussion: Hemophilia Part 2

On June 6, 2025, Malissa Norfolk and Dave Cabral posted George’s audio PowerPoint, “Have We Cured Hemophilia, Part 1?.” On June 25, Malissa and Dave posted “Have We Cured Hemophilia, Part 2?” Each video is 30″ long. Please feel free to watch and comment below.

Bleeding Disorders

DIC Update

On Monday, June 23, Ecaterina (Katy) Scarlatescu, MD, PhD, Department of Anaesthesia and Intensive Care, Fundeni Clinical Institute, University of Medicine and Pharmacy, Bucharest, Romania, chaired a plenary session of panelists at the ISTH annual meeting in Washington, DC, USA. The panel discussed the 2025 ISTH DIC definition and diagnostic guidelines we reported on June […]

Thrombophilia

Lab Assessment of FVIII Inhibitors

Click here for an open-access article describing the need for factor inhibitor assessment: Favaloro EJ, Curnow J, Pasalic L. Laboratory assessment of factor VIII inhibitors: when is it required? A perspective informed by local practice. J Clin Med. 2024;14:13. doi: 10.3390/jcm14010013. PMID: 39797095; PMCID: PMC11720995. See also our factor inhibitor discussions under the Bleeding Disorders heading.

Comments (0)

Bleeding Disorders

Bleeding Disorders

Thrombotic Thrombocytopenic Purpura

July 2025 QQ: Hemophilia Rebalancing Therapy

Status of Gene-based Hemophilia A and B Therapy

Autoimmune Acquired Coagulation Factor Deficiencies

Postpartum DIC

Genetic Study on VWD Variants

July 2025 Quick Question: Hemophilia Therapeutics

Differential Discussion: Hemophilia Part 2

DIC Update

Lab Assessment of FVIII Inhibitors

George Fritsma MS MLS

Cheat Sheets from George

Questions or Comments?

Quick Question